2020 Insights into Retinitis Pigmentosa (RP) - Epidemiology Forecast to 2030 - ResearchAndMarkets.com

·4 min read

The "Retinitis Pigmentosa (RP) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical and forecasted Retinitis Pigmentosa (RP) epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent Cases of Retinitis Pigmentosa in the 7MM, Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM, Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM, Subtype-Specific Diagnosed Prevalence of Syndromic and Systemic RP in the 7MM, and Subtype-specific Diagnosed Prevalent Cases of Non-Syndromic RP in the 7MM) scenario of Retinitis Pigmentosa in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017-2030.

Retinitis Pigmentosa (RP) Detailed Epidemiology Segmentation

According to the publisher's, the total diagnosed prevalent population of Retinitis Pigmentosa (RP) in the 7MM is 253,420 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

The estimates show the highest diagnosed prevalence of RP in the United States with 108,787 cases in 2017.

Among the European 5 countries, Germany had the highest diagnosed prevalent population of RP with 30,642 cases, followed by France and the United Kingdom. On the other hand, Spain had the lowest diagnosed prevalent population of 17,236 cases in 2017.

As per the analysis, a higher percentage of diagnosed prevalence was observed for males, in comparison to females, in all the 7MM countries, except Japan, where females occupy a larger patient pool than males.

Based on the type of RP, it has been assessed that the majority of the patients suffer from non-syndromic RP, with 172,256 cases observed in the 7MM, in 2017, while syndromic and systemic RP cases account for nearly one-fourth of the total RP population.

Scope of the Report

  • The report covers the descriptive overview of Retinitis Pigmentosa (RP), explaining its causes, signs and symptoms, and pathogenesis.

  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan.

  • The report assesses the disease risk and burden and highlights the unmet needs of Retinitis Pigmentosa (RP).

  • The report helps to recognize the growth opportunities in the seven major market with respect to the patient population.

  • The report provides the segmentation of the disease epidemiology at the 7MM level by Total Prevalent Population, Gender-specific diagnosed prevalence, Type-specific diagnosed prevalence, Subtype-specific diagnosed prevalence of syndromic and systemic RP, and Subtype-specific diagnosed prevalent cases of non-syndromic RP.

Key Questions Answered

  1. What is the disease risk, burden and unmet needs of Retinitis Pigmentosa?

  2. What is the historical Retinitis Pigmentosa patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?

  3. What would be the forecasted patient pool of Retinitis Pigmentosa at the 7MM level?

  4. What will be the growth opportunities across the globe with respect to the patient population pertaining to Retinitis Pigmentosa?

  5. Out of the above-mentioned countries, which country would have the highest Incident population of Retinitis Pigmentosa during the forecast period (2020-2030)?

  6. At what CAGR the population is expected to grow across the globe during the forecast period (2020-2030)?

Reasons to Buy

  • Develop business strategies by understanding the trends shaping and driving the 7MM Retinitis Pigmentosa.

  • Quantify patient populations in the 7MM Retinitis Pigmentosa market to improve product design, pricing, and launch plans.

  • Organize sales and marketing efforts by identifying the causative pathogen that presents the best opportunities for Retinitis Pigmentosa therapeutics in each of the markets covered.

  • The Retinitis Pigmentosa epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.

  • The Retinitis Pigmentosa epidemiology model is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

For more information about this report visit https://www.researchandmarkets.com/r/hakv6z

View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005832/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900